Mirador Capital Partners’s Tenaya Therapeutics TNYA Stock Holding History

Mirador Capital Partners’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$578K	Buy	957,204 +52,107	+6%	+$38K	0.07%	147
2026 Q2	$669K	Buy	905,097 +18,180	+2%	+$13.8K	0.08%	129
2026 Q1	$614K	Buy	886,917 +304,393	+52%	+$225K	0.09%	128
2025 Q4	$414K	Buy	582,524 +559,024	+2,379%	+$760K	0.06%	157
2025 Q3	$38.1K	Buy	23,500 +6,500	+38%	+$6.55K	0.01%	214
2025 Q2	$10.4K	Buy	17,000 +2,000	+13%	+$1.02K	﹤0.01%	200
2025 Q1	$8.55K	Buy	+15,000	New	+$14.8K	﹤0.01%	197

Other funds holding TNYA

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GGS

Galvin Gaustad & Stein Scottsdale, Arizona $1.33B AUM 13.15% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Mirador Capital Partners's TNYA Position: Q3 2026 in Review

Mirador Capital Partners increased its Tenaya Therapeutics (TNYA) stake by 5.8% in Q3 2026, buying an estimated $38K and bringing the position to 957,204 shares worth $578K. The position accounts for 0.07% of the portfolio, ranked #147.

Mirador Capital Partners first reported a position in TNYA in Q1 2025 and has held it in 7 quarters since. The position peaked at $669K in Q2 2026. 5 funds tracked by Wall St. Rank hold TNYA as of Q3 2026.

Mirador Capital Partners held 957,204 shares of Tenaya Therapeutics worth $578K as of Q3 2026.
Mirador Capital Partners bought 52,107 Tenaya Therapeutics shares in Q3 2026, an estimated $38K.
Tenaya Therapeutics made up 0.07% of Mirador Capital Partners's portfolio in Q3 2026, its #147 holding.
Mirador Capital Partners first reported a position in Tenaya Therapeutics in Q1 2025 and has held it in 7 quarters since.
Mirador Capital Partners's Tenaya Therapeutics position peaked at $669K in Q2 2026.
5 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2026.

Based on Mirador Capital Partners's 13F filing for Q3 2026, filed 9 Oct 2026.